US High Growth Tech Stocks To Watch Now

The United States market has shown a positive trajectory, rising 1.2% over the last week and 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In this environment, identifying high growth tech stocks involves looking for companies that can sustain robust earnings growth and capitalize on technological advancements amidst favorable market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
AppLovin	21.01%	21.71%	★★★★★★
Sandisk	39.74%	40.96%	★★★★★★
Reddit	21.88%	25.36%	★★★★★★
Krystal Biotech	29.09%	36.48%	★★★★★★
Palantir Technologies	30.22%	31.80%	★★★★★★
Fabrinet	21.38%	23.34%	★★★★★★
Marker Therapeutics	64.28%	69.04%	★★★★★★
Gorilla Technology Group	54.35%	96.69%	★★★★★☆
KVH Industries	28.67%	146.09%	★★★★★☆
Zscaler	15.84%	49.86%	★★★★★☆

Click here to see the full list of 70 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Daktronics (DAKT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Daktronics, Inc. is a company that designs, manufactures, and sells electronic scoreboards and display systems for various applications including sports, commercial venues, and transportation both domestically and internationally, with a market capitalization of approximately $979.97 million.

Operations: The company generates revenue through five main segments: Commercial ($181.01 million), Live Events ($295.79 million), International ($76.98 million), Transportation ($71.43 million), and High School Park and Recreation ($177.44 million).

Daktronics has demonstrated a remarkable earnings growth of 2561.6% over the past year, significantly outpacing the electronic industry's average of 13.4%. This surge is attributed to strategic expansions and technological enhancements, such as the recent installation of advanced LED displays at Yankee Stadium and other major venues, which total over 22,355 square feet of digital canvas. These installations not only enhance fan experience with high-resolution imagery and dynamic content zoning but also solidify Daktronics' presence in high-profile sports settings. Despite a slower projected revenue growth rate of 8.3% compared to the US market's 11.7%, Daktronics' earnings are expected to grow by an impressive 35.6% annually over the next three years, suggesting robust profit potential driven by innovation and market expansion strategies.

• Click here to discover the nuances of Daktronics with our detailed analytical health report.

• Gain insights into Daktronics' past trends and performance with our Past report.

Neurocrine Biosciences (NBIX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and commercialization of pharmaceuticals targeting neurological, psychiatric, endocrine, and immunological disorders globally with a market cap of $15.76 billion.

Operations: The company generates revenue primarily through the research, development, and commercialization of pharmaceuticals, with reported sales of $3.10 billion.

Neurocrine Biosciences has recently showcased robust growth and innovation, particularly with its INGREZZA capsules, which have significantly improved symptoms of tardive dyskinesia (TD), enhancing patient's quality of life. The company reported a substantial increase in Q1 revenue to $814.5 million from $572.6 million year-over-year and a surge in net income to $197.9 million from just $7.9 million, indicating strong financial health and effective strategy execution. Furthermore, the initiation of a secured credit facility worth $1 billion underscores their strategic financial management aimed at fueling further research and development initiatives, ensuring sustained growth in their specialized pharmaceutical offerings.

• Click here and access our complete health analysis report to understand the dynamics of Neurocrine Biosciences.

• Evaluate Neurocrine Biosciences' historical performance by accessing our past performance report.

Klaviyo (KVYO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Klaviyo, Inc. offers a cloud-based software-as-a-service platform across various regions including the United States, Asia-Pacific, Europe, and more, with a market cap of $4.45 billion.

Operations: Klaviyo generates revenue primarily from its Internet Software segment, amounting to $1.31 billion. The company operates a cloud-based software-as-a-service platform across multiple regions, including the United States and Asia-Pacific.

Klaviyo's recent integration with Anthropic to enhance Claude's capabilities marks a strategic move in AI-driven marketing, reflecting its innovative approach to handling complex data workflows efficiently. This development complements their Q1 financial performance, where they turned a net profit of $9.04 million from a previous loss and posted revenues of $358.01 million, up from $279.83 million year-over-year—an impressive 28% increase. These advancements are pivotal as Klaviyo continues to expand its technological footprint and adapt to dynamic market demands, positioning itself robustly within the tech landscape despite CFO Amanda Whalen stepping down later this year.

• Navigate through the intricacies of Klaviyo with our comprehensive health report here.

• Review our historical performance report to gain insights into Klaviyo's's past performance.

Next Steps

• Dive into all 70 of the US High Growth Tech and AI Stocks we have identified here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com